KalVista Pharmaceuticals (KALV) Insider Trading & Ownership $10.15 +0.83 (+8.91%) (As of 11/22/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends KalVista Pharmaceuticals (NASDAQ:KALV) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage10.50%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$5.81 MNumber OfInsiders Selling(Last 12 Months)5Amount OfInsider Selling(Last 12 Months)$2.97 M Get KALV Insider Trade Alerts Want to know when executives and insiders are buying or selling KalVista Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address KALV Insider Buying and Selling by Quarter Ad Priority GoldJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. KalVista Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails11/18/2024Benjamin L PalleikoCEOSell14,400$9.26$133,344.00 11/18/2024Paul K AudhyaInsiderSell8,077$9.26$74,793.02 9/9/2024Benjamin L PalleikoCEOSell7,352$12.19$89,620.88 8/23/2024Paul K AudhyaInsiderSell2,135$12.40$26,474.00 8/19/2024Benjamin L PalleikoCEOSell14,215$12.01$170,722.15 8/19/2024Christopher YeaInsiderSell7,102$12.01$85,295.02 Trump Wins… But Elon Says Get Ready to Brace (Ad)Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back…Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov6/7/2024Benjamin L PalleikoCEOSell7,465$11.53$86,071.45 5/20/2024Benjamin L PalleikoCEOSell21,959$11.76$258,237.84 5/20/2024Edward P FeenerInsiderSell8,088$11.76$95,114.88 2/20/2024Benjamin L PalleikoCFOSell22,802$14.11$321,736.22 2/20/2024Edward P FeenerInsiderSell28,288$14.07$398,012.16 2/20/2024Thomas Andrew CrockettCEOSell24,888$14.11$351,169.68 2/8/2024Venrock Healthcare Capital ParMajor ShareholderBuy29,747$14.70$437,280.90 2/6/2024Venrock Healthcare Capital ParMajor ShareholderBuy4,474$14.74$65,946.76 1/29/2024Venrock Healthcare Capital ParMajor ShareholderBuy80,600$14.22$1,146,132.00 1/26/2024Venrock Healthcare Capital ParMajor ShareholderBuy4,174$12.98$54,178.52 1/24/2024Venrock Healthcare Capital ParMajor ShareholderBuy20,686$12.44$257,333.84 1/22/2024Venrock Healthcare Capital ParMajor ShareholderBuy67,546$12.55$847,702.30 1/18/2024Venrock Healthcare Capital ParMajor ShareholderBuy39,680$12.51$496,396.80 1/16/2024Venrock Healthcare Capital ParMajor ShareholderBuy19,599$12.73$249,495.27 1/11/2024Edward P FeenerInsiderSell22,679$13.03$295,507.37 1/10/2024Venrock Healthcare Capital ParMajor ShareholderBuy47,700$12.67$604,359.00 1/8/2024Edward P FeenerInsiderSell17,221$13.01$224,045.21 1/8/2024Venrock Healthcare Capital ParMajor ShareholderBuy69,184$12.44$860,648.96 1/3/2024Venrock Healthcare Capital ParMajor ShareholderBuy17,605$12.20$214,781.00 12/29/2023Venrock Healthcare Capital ParMajor ShareholderBuy6,013$12.49$75,102.37 12/27/2023Thomas Andrew CrockettCEOSell30,000$12.02$360,600.00 12/27/2023Venrock Healthcare Capital ParMajor ShareholderBuy41,514$11.97$496,922.58 (Data available from 1/1/2013 forward) KALV Insider Trading Activity - Frequently Asked Questions Who is on KalVista Pharmaceuticals's Insider Roster? The list of insiders at KalVista Pharmaceuticals includes Albert Cha, Benjamin L Palleiko, Christopher Yea, Edward P Feener, Paul K Audhya, Thomas Andrew Crockett, and Venrock Healthcare Capital Par. Learn more on insiders at KALV. What percentage of KalVista Pharmaceuticals stock is owned by insiders? 10.50% of KalVista Pharmaceuticals stock is owned by insiders. Learn more on KALV's insider holdings. Which KalVista Pharmaceuticals insiders have been buying company stock? The following insider purchased KALV shares in the last 24 months: Venrock Healthcare Capital Par ($5,806,280.30). How much insider buying is happening at KalVista Pharmaceuticals? Insiders have purchased a total of 448,522 KALV shares in the last 24 months for a total of $5,806,280.30 bought. Which KalVista Pharmaceuticals insiders have been selling company stock? The following insiders have sold KALV shares in the last 24 months: Albert Cha ($189,000.00), Benjamin L Palleiko ($1,278,824.27), Christopher Yea ($111,699.58), Edward P Feener ($1,012,679.62), Paul K Audhya ($213,457.54), and Thomas Andrew Crockett ($979,768.94). How much insider selling is happening at KalVista Pharmaceuticals? Insiders have sold a total of 317,968 KalVista Pharmaceuticals shares in the last 24 months for a total of $3,785,429.95 sold. KalVista Pharmaceuticals Key ExecutivesMr. Benjamin L. Palleiko (Age 58)CEO & Director Compensation: $983.07k4 recent tradesDr. Christopher M. Yea Ph.D. (Age 60)Chief Development Officer Compensation: $708.53kDr. Paul K. Audhya M.B.A. (Age 51)M.D., Chief Medical Officer Compensation: $736.82kMr. Brian Piekos (Age 49)Chief Financial Officer Mr. Ryan BakerHead of Investor RelationsMr. Brian Krex J.D. (Age 56)General Counsel Jarrod AldomVice President of Corporate CommunicationsMs. Rachel M. MortenSenior Vice President of Regulatory Affairs & QADr. Michael D. Smith Pharm.D. (Age 44)Senior Vice President of Development Ms. Nicole Sweeny (Age 48)Chief Commercial Officer More Insider Trading Tools from MarketBeat Related Companies ALIM Insider Selling BCRX Insider Selling NRIX Insider Selling SAVA Insider Selling KNSA Insider Selling TVTX Insider Selling NTLA Insider Selling SYRE Insider Selling PRAX Insider Selling DAWN Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Selling Into 3 Rallies: Investors Should Do the OppositeInsiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking On This page (NASDAQ:KALV) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KalVista Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KalVista Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KALV Stock Alerts